Lumito AB publishes Quarterly Report 1, 2022
Lumito AB publishes Quarterly Report 1, 2022 Financial overview of the first quarter January 1 to March 31, 2022 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -6 430 (-6 825). Earnings per share before and after dilution amounted to SEK -0.04 (-0.08). Cash flow from operating […]
Lumito signs cooperation agreement with Optronic for 0-series production of the company’s scanner
Lumito AB and Optronic Partner pr AB have signed a cooperation agreement for the final design, industrialization and 0-series production of Lumito's first Whole Slide Imaging (WSI) scanners. The scope of the agreement is based on the delivery of 0-series production prior to Lumito's planned launch for research laboratories at the end of 2022. The […]
Year-end report 2021, Lumito AB (publ)
Financial overview 1 October – 31 December 2021 Net sales amounted to KSEK 0 (0) Result after taxes amounted to KSEK -6 855 (-5 199). Basic and diluted earnings per share amounted to SEK -0.08 (-0.06). Cash flow from operating activities after change in working capital amounted to KSEK -2 270 (-5 032). Twelve months, 1 January – 31 […]
Images of high and stable quality offer excellent assessment possibilities
Lumito’s objective is to create high-quality stainings of tissue sections and corresponding imaging. A key effort has been to achieve a repeatable and robust staining methodology that can generate imaging that is optimal for a digital, visual evaluation. These objectives have now been achieved, according to Dr. Bo Holmqvist. Bo Holmqvist (CSO, Imagene-iT AB) has […]
Strategy update. Product launch in research laboratories planned for the end of 2022
By launching a product for research laboratories, Lumito enables market access by late 2022. The Company considers that there is business potential in research laboratories, which may generate sales as of 2022. In addition, it may draw media attention to the Company's technology and deepen understanding of the opportunities offered by the technology, moving forward. […]
Lumito AB publishes Quarterly Report 3, 2021
Financial overview Third quarter, January–September 2021 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -19,517 (-10,848). Basic and diluted earnings per share amounted to SEK -0.22 (-0.15). Cash flow from operating activities after change in working capital amounted to KSEK -19,927 (-12,239). Cash and cash equivalents amounted to KSEK […]
Correction of previously published press release concerning the early publication of the quarterly report
The press release published on 18 October at 13.00 contains incorrect information, as the Quarterly Report 3 2021 has not been audited. For further information, please contact: Lumito's CEO, Mattias Lundin e-mail: ml@lumito.se phone: 076-868 45 09 Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide […]
Earlier quarterly report in Lumito AB (publ)
Lumito AB (publ) hereby announces that the Board of Directors has decided to bring forward the company's report for quarter 3, 2021 to 20 October 2021, as the compilation work has progressed faster than expected and the auditors have reviewed the report. The Company's financial calendar has been updated and can be found here. For […]
Change of mentor to Mangold Fondkommission
Lumito AB has entered into an agreement with Mangold Fondkommission AB to act as the company's mentor in trading on NGM Nordic SME. Mangold Fondkommission will take over as mentor for the company on 15 October 2021. Lumito has simultaneously terminated the agreement with G&W Fondkommission AB, which expired on 14 October 2021. For further […]
Scanner with improved functionality installed
A life science consultant from TTP plc has delivered the next version of the Lumito’s scanner, with improved functionality, and assisted in the installation process. The new scanner entails, among other things, greater capacity to test new indications and to complete the evaluation of the breast cancer marker Her2. – Due to the pandemic, this was […]